Vertex Pharmaceuticals, Inc. (VRTX)
504.73
-2.01
(-0.40%)
USD |
NASDAQ |
Oct 02, 16:00
505.10
+0.37
(+0.07%)
After-Hours: 20:00
Vertex Pharmaceuticals Enterprise Value : 121.99B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 121.99B |
| October 01, 2026 | 122.50B |
| September 30, 2026 | 126.57B |
| September 29, 2026 | 127.56B |
| September 28, 2026 | 127.80B |
| September 25, 2026 | 127.42B |
| September 24, 2026 | 126.46B |
| September 23, 2026 | 124.93B |
| September 22, 2026 | 124.59B |
| September 21, 2026 | 123.50B |
| September 18, 2026 | 122.90B |
| September 17, 2026 | 124.93B |
| September 16, 2026 | 124.15B |
| September 15, 2026 | 124.49B |
| September 14, 2026 | 125.73B |
| September 11, 2026 | 124.70B |
| September 10, 2026 | 124.48B |
| September 09, 2026 | 126.14B |
| September 08, 2026 | 128.11B |
| September 04, 2026 | 132.47B |
| September 03, 2026 | 135.47B |
| September 02, 2026 | 135.17B |
| September 01, 2026 | 132.86B |
| August 31, 2026 | 132.07B |
| August 28, 2026 | 131.35B |
| Date | Value |
|---|---|
| August 27, 2026 | 132.84B |
| August 26, 2026 | 132.77B |
| August 25, 2026 | 134.18B |
| August 24, 2026 | 132.85B |
| August 21, 2026 | 132.96B |
| August 20, 2026 | 130.99B |
| August 19, 2026 | 133.98B |
| August 18, 2026 | 127.93B |
| August 17, 2026 | 124.73B |
| August 14, 2026 | 122.25B |
| August 13, 2026 | 124.95B |
| August 12, 2026 | 127.31B |
| August 11, 2026 | 128.30B |
| August 10, 2026 | 126.85B |
| August 07, 2026 | 119.79B |
| August 06, 2026 | 116.74B |
| August 05, 2026 | 116.95B |
| August 04, 2026 | 115.39B |
| August 03, 2026 | 113.37B |
| July 31, 2026 | 114.99B |
| July 30, 2026 | 116.15B |
| July 29, 2026 | 116.57B |
| July 28, 2026 | 118.35B |
| July 27, 2026 | 115.47B |
| July 24, 2026 | 115.05B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Alnylam Pharmaceuticals, Inc. | 29.06B |
| Gilead Sciences, Inc. | 200.90B |
| Sionna Therapeutics, Inc. | 18.79M |
| Regeneron Pharmaceuticals, Inc. | 70.72B |
| Ionis Pharmaceuticals, Inc. | 7.346B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 1.100B |
| Revenue (Quarterly) | 3.344B |
| Total Expenses (Quarterly) | 2.244B |
| EPS Diluted (Quarterly) | 4.310 |
| Gross Profit Margin (Quarterly) | 85.37% |
| Profit Margin (Quarterly) | 32.89% |
| Earnings Yield | 3.41% |
| Operating Earnings Yield | 3.88% |
| Normalized Earnings Yield | 3.499 |